Quanterix prices public offering of common stock

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. Quanterix has also granted the underwriters a 30-day option to purchase up to an additional 356,435 shares of common stock on the same terms and conditions.

The offering is expected to close on or about August 13, 2019, subject to customary closing conditions.

J.P. Morgan Securities LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as co-manager for the offering. Perella Weinberg Partners is acting as independent capital markets advisor to Quanterix for the offering.

The public offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6132 or by e-mail at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quanterix. (2019, October 25). Quanterix prices public offering of common stock. News-Medical. Retrieved on September 29, 2023 from https://www.news-medical.net/news/20190809/Quanterix-prices-public-offering-of-common-stock.aspx.

  • MLA

    Quanterix. "Quanterix prices public offering of common stock". News-Medical. 29 September 2023. <https://www.news-medical.net/news/20190809/Quanterix-prices-public-offering-of-common-stock.aspx>.

  • Chicago

    Quanterix. "Quanterix prices public offering of common stock". News-Medical. https://www.news-medical.net/news/20190809/Quanterix-prices-public-offering-of-common-stock.aspx. (accessed September 29, 2023).

  • Harvard

    Quanterix. 2019. Quanterix prices public offering of common stock. News-Medical, viewed 29 September 2023, https://www.news-medical.net/news/20190809/Quanterix-prices-public-offering-of-common-stock.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Quanterix launches LucentAD Biomarker blood test to aid physician diagnosis of Alzheimer’s disease in patients